I don't usually write about the starts of clinical trials, and I've even been known to send snarky replies to PR people who pitch them to me via email. I mean, really, tell me when the thing ends; that's the data investors care about, since it drives the stock price.
So I found it curious that CEL-SCI
Did CEL-SCI suddenly figure out a way to start and complete a clinical trial in one day? Was there something in the press release that gave investors additional confidence that Multikine would work? Not that I can see.
As best I can tell, this was just investors saying, "Finally!" The trial, which it's running with Teva Pharmaceutical
There's likely also a little excitement as investors look at CEL-SCI as the next Dendreon
The phase 3 trial looks well-planned, but I don't see much reason to jump in at this point. It's not clear that Multikine will work -- the phase 2 trial didn't have a control group -- and it's going to take a long time to get an answer. The endpoint is overall survival, which CEL-SCI believes will take three years in the standard of care group and hopefully longer in the Multikine group.
Investors looking for a company that's a little further along would be better off looking at Regeneron Pharmaceuticals
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool owns shares of Teva and has a disclosure policy.